Scilex Holding Company announced that one Midwestern and one Southern State voted to add ZTlido as a preferred agent to their Medicaid Preferred Drug List (PDLs) effective as of January 1, 2024. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022.

Scilex participated in the type C meeting for purposes of pre-NDA discussion with the FDA and reached agreement on a path forward to file an NDA for SP-102 (SEMDEXA in Lumbosacral Radicular Pain (Sciatica) with the FDA. Scilex launched its first commercial product ZTlido, in-licensed a commercial product Gloperba in June 2022, and launched its third FDA-approved product Elyxyb in April 2023.